We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Scancell
Successful SCOPE outcome and iSCIB1+ selectionScancell
Key ImmunoBody clinical data imminentHUTCHMED
Orpathys/Tagrisso combination approved in ChinaOxford BioDynamics
H125: working towards delivering on objectivesAvacta
Beneath the tip of the pre|CISION icebergScancell
Cancer vaccine data due soon; Glymab developments tooANGLE
Priming the Pharma Services marketAvacta
FY24: shift to pure play biopharma nears completionHUTCHMED
SACHI details de-risk savolitinib potential approvalsANGLE
Building a pharma partnership pipeline… and medtech too